Pub Date : 2025-05-07eCollection Date: 2025-01-01DOI: 10.1155/dim/9862076
Disease Markers
[This retracts the article DOI: 10.1155/2019/8186091.].
[本文撤回文章DOI: 10.1155/2019/8186091]。
{"title":"RETRACTION: AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion.","authors":"Disease Markers","doi":"10.1155/dim/9862076","DOIUrl":"https://doi.org/10.1155/dim/9862076","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1155/2019/8186091.].</p>","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2025 ","pages":"9862076"},"PeriodicalIF":0.0,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-26eCollection Date: 2025-01-01DOI: 10.1155/dim/9803765
Disease Markers
[This retracts the article DOI: 10.1155/2018/4272064.].
[本文撤回文章DOI: 10.1155/2018/4272064]。
{"title":"RETRACTION: Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances Cell Proliferation, Migration, and Invasion in Bladder Cancer.","authors":"Disease Markers","doi":"10.1155/dim/9803765","DOIUrl":"10.1155/dim/9803765","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1155/2018/4272064.].</p>","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2025 ","pages":"9803765"},"PeriodicalIF":0.0,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-31eCollection Date: 2025-01-01DOI: 10.1155/dim/9838093
Disease Markers
[This retracts the article DOI: 10.1155/2022/5141927.].
[此撤回文章DOI: 10.1155/2022/5141927.]。
{"title":"RETRACTION: HuR Promotes the Progression of Gastric Cancer through Mediating CDC5L Expression.","authors":"Disease Markers","doi":"10.1155/dim/9838093","DOIUrl":"https://doi.org/10.1155/dim/9838093","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1155/2022/5141927.].</p>","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2025 ","pages":"9838093"},"PeriodicalIF":0.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11976036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-22eCollection Date: 2025-01-01DOI: 10.1155/dim/9878012
Disease Markers
[This retracts the article DOI: 10.1155/2020/8140989.].
[本文撤回文章DOI: 10.1155/2020/8140989.]。
{"title":"RETRACTION: Long Noncoding RNA AFAP1-AS1 Promotes Cell Proliferation and Metastasis via the miR-155-5p/FGF7 Axis and Predicts Poor Prognosis in Gastric Cancer.","authors":"Disease Markers","doi":"10.1155/dim/9878012","DOIUrl":"10.1155/dim/9878012","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1155/2020/8140989.].</p>","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2025 ","pages":"9878012"},"PeriodicalIF":0.0,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-07eCollection Date: 2024-01-01DOI: 10.1155/2024/8278727
Neda M Bogari, Ahmad O Babalghith, Zohor Asaad Azher, Ahmad Hasan Mufti, Abdellatif Bouazzaoui, Hussain Banni, Abdulelah Awaji Madkhali, Ahmed Alahmadi, Reem M Allam
Background: Coronary artery diseases may be affected by several genetic and nongenetic factors. Single-nucleotide polymorphism (SNP) rs599839 and type 2 diabetes mellitus (T2DM) can affect the occurrence and severity of coronary artery disease (CAD).
Methods: Our aim was to investigate how T2DM and the rs599839 variant affected serum lipid levels and the degree of CAD patients' coronary artery stenosis. rs599839 polymorphism genotyping was done on Saudi patients with coronary angiography performed previously. Patients enrolled were divided into group A (360 DM patients), group B (225 DM patients with CAD), and group C (190 healthy volunteers as control).
Results: Individuals with diabetes and CAD who possessed the GG genotype in rs599839 exhibited markedly reduced means of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG; 224.5, 116.2, and 221.4 versus 251.6, 131.3, and 261.7 mg/dl, p=0.003, 0.007, and 0.025, respectively) than AA genotype. The odds ratio and the confidence interval of 95% for G allele carriers of rs599839 were OR = 0.62, 95% CI: 0.41-0.82, and p=0.003, among diabetic patients with CAD.
Conclusions: In patients with diabetic CAD, the locus 1p13.3 polymorphism rs599839 was found to be substantially correlated with serum lipid levels. Furthermore, among Saudi patients with diabetes, the G allele of rs599839 variant lowers the CAD risk.
背景：冠状动脉疾病可能受到多种遗传和非遗传因素的影响。单核苷酸多态性（SNP）rs599839和2型糖尿病（T2DM）会影响冠状动脉疾病（CAD）的发生和严重程度：我们的目的是研究 T2DM 和 rs599839 变体如何影响血清脂质水平和 CAD 患者的冠状动脉狭窄程度。入组患者被分为 A 组（360 名糖尿病患者）、B 组（225 名患有 CAD 的糖尿病患者）和 C 组（190 名健康志愿者作为对照）：结果：与 AA 基因型相比，rs599839 基因型为 GG 的糖尿病和 CAD 患者的总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）和甘油三酯（TG；分别为 224.5、116.2 和 221.4 对 251.6、131.3 和 261.7 mg/dl，P=0.003、0.007 和 0.025）均明显降低。在患有 CAD 的糖尿病患者中，rs599839 的 G 等位基因携带者的几率比和 95% 的置信区间分别为 OR = 0.62、95% CI：0.41-0.82 和 p=0.003：结论：在糖尿病并发心血管疾病患者中，1p13.3位点多态性rs599839与血清脂质水平密切相关。此外，在沙特籍糖尿病患者中，rs599839 变异的 G 等位基因可降低 CAD 风险。
{"title":"Impact of rs599839 Polymorphism on Coronary Artery Disease Risk in Saudi Diabetic Patients.","authors":"Neda M Bogari, Ahmad O Babalghith, Zohor Asaad Azher, Ahmad Hasan Mufti, Abdellatif Bouazzaoui, Hussain Banni, Abdulelah Awaji Madkhali, Ahmed Alahmadi, Reem M Allam","doi":"10.1155/2024/8278727","DOIUrl":"10.1155/2024/8278727","url":null,"abstract":"<p><strong>Background: </strong>Coronary artery diseases may be affected by several genetic and nongenetic factors. Single-nucleotide polymorphism (SNP) rs599839 and type 2 diabetes mellitus (T2DM) can affect the occurrence and severity of coronary artery disease (CAD).</p><p><strong>Methods: </strong>Our aim was to investigate how T2DM and the rs599839 variant affected serum lipid levels and the degree of CAD patients' coronary artery stenosis. rs599839 polymorphism genotyping was done on Saudi patients with coronary angiography performed previously. Patients enrolled were divided into group A (360 DM patients), group B (225 DM patients with CAD), and group C (190 healthy volunteers as control).</p><p><strong>Results: </strong>Individuals with diabetes and CAD who possessed the GG genotype in rs599839 exhibited markedly reduced means of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG; 224.5, 116.2, and 221.4 versus 251.6, 131.3, and 261.7 mg/dl, <i>p</i>=0.003, 0.007, and 0.025, respectively) than AA genotype. The odds ratio and the confidence interval of 95% for G allele carriers of rs599839 were OR = 0.62, 95% CI: 0.41-0.82, and <i>p</i>=0.003, among diabetic patients with CAD.</p><p><strong>Conclusions: </strong>In patients with diabetic CAD, the locus 1p13.3 polymorphism rs599839 was found to be substantially correlated with serum lipid levels. Furthermore, among Saudi patients with diabetes, the G allele of rs599839 variant lowers the CAD risk.</p>","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2024 ","pages":"8278727"},"PeriodicalIF":0.0,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Indra Wijaya, Muhammad H. Bashari, Lelani Reniarti, Anita Rahmawati, Rully M. A. Roesli
Background. Chronic myeloid leukemia (CML) or chronic granulocytic leukemia is a myeloproliferative neoplasm indicated by the presence of the Philadelphia (Ph+) chromosome. First-line tyrosine kinase inhibitor, imatinib, is the gold standard for treatment. However, there has been known unresponsiveness to treatment, especially due to the involvement of other genes, such as the Janus kinase 2 (JAK2) gene. This study aimed to evaluate the relationships between JAK2 levels and complete hematological response (CHR), as well as early molecular response (EMR) after 3 months of imatinib treatment in patients with chronic phase CML. Methods. Patients with Ph+ CML in the chronic phase (n = 40; mean age, 40 ± 11 years) were recruited to complete assessments consisting of clinical examination and blood test, including evaluation of complete blood counts and the JAK2 levels, at baseline and following 3 months of therapy with imatinib (at an oral dose of 400 mg per day). Subjects were divided into two groups according to the presence of CHR and EMR. Results. JAK2 gene levels, phosphorylated, and total JAK2 proteins at baseline were significantly lower in the group with the presence of CHR and EMR. In addition, baseline JAK2 levels, including JAK2 gene expression, phosphorylated, and total JAK2 proteins, were negatively correlated with the presence of CHR and EMR. Conclusions. Based on these findings, JAK2 levels may be a potential indicator for evaluating treatment response on imatinib due to its role in the pathophysiology of CML.
{"title":"JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib","authors":"Indra Wijaya, Muhammad H. Bashari, Lelani Reniarti, Anita Rahmawati, Rully M. A. Roesli","doi":"10.1155/2024/2906566","DOIUrl":"https://doi.org/10.1155/2024/2906566","url":null,"abstract":"<i>Background</i>. Chronic myeloid leukemia (CML) or chronic granulocytic leukemia is a myeloproliferative neoplasm indicated by the presence of the Philadelphia (Ph+) chromosome. First-line tyrosine kinase inhibitor, imatinib, is the gold standard for treatment. However, there has been known unresponsiveness to treatment, especially due to the involvement of other genes, such as the Janus kinase 2 (JAK2) gene. This study aimed to evaluate the relationships between JAK2 levels and complete hematological response (CHR), as well as early molecular response (EMR) after 3 months of imatinib treatment in patients with chronic phase CML. <i>Methods</i>. Patients with Ph+ CML in the chronic phase (<i>n</i> = 40; mean age, 40 ± 11 years) were recruited to complete assessments consisting of clinical examination and blood test, including evaluation of complete blood counts and the JAK2 levels, at baseline and following 3 months of therapy with imatinib (at an oral dose of 400 mg per day). Subjects were divided into two groups according to the presence of CHR and EMR. <i>Results</i>. JAK2 gene levels, phosphorylated, and total JAK2 proteins at baseline were significantly lower in the group with the presence of CHR and EMR. In addition, baseline JAK2 levels, including JAK2 gene expression, phosphorylated, and total JAK2 proteins, were negatively correlated with the presence of CHR and EMR. <i>Conclusions</i>. Based on these findings, JAK2 levels may be a potential indicator for evaluating treatment response on imatinib due to its role in the pathophysiology of CML.","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140563134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atif Ali Hashmi, Bakhtawar Allauddin Mallick, Khushbakht Rashid, Umair Arshad Malik, Shamail Zia, Fazail Zia, Muhammad Irfan
Introduction. Metaplastic breast carcinoma (MBC) is a rare subgroup of breast neoplasms associated with adverse outcomes because of its aggressive nature. Typically, MBCs show triple-negative hormone receptor (HR) status. Determining the HR status of breast cancer is an integral part because it is an important prognostic factor and helps in the treatment course of the disease. This study aimed to determine the HR status of MBC, its significance, and its association with various clinicopathological parameters. Methods. This was a retrospective study conducted at the Department of Histopathology, Liaquat National Hospital. A total of 140 biopsy-proven cases of MBC were enrolled in the study. Clinical and pathological data were retrieved from the institutes’ archives. Immunohistochemical studies were conducted to determine the estrogen receptor (ER) and progesterone receptor (PR) status. Results. The mean age of MBC in our population was found to be 52.18 ± 12.19 years. The HR positivity rate in our population was found to be 32.9%. A significant association was found between HR status and tumor laterality, tumor size, tumor grade, tumor stage, and recurrence. ER/PR-negative MBCs were most probably associated with higher grade and higher tumor stage and were larger in size (6.62 ± 3.43 cm) than ER/PR-positive MBCs (4.20 ± 1.88 cm). Moreover, ER/PR-positive MBCs showed a higher recurrence rate than ER/PR-negative MBCs (43.5% vs. 25.5%, respectively). No statistically significant relationship was found between HR status and patient age, histological subtype, or survival rate. Conclusion. MBC is a rare breast neoplasm. MBC was found to be triple negative in most cases, but a significant percentage were HR (ER/PR) positive. Moreover, we found an association between HR status and various clinicopathological features, indicating that HR status is a significant predictor of MBC prognosis.
简介移行细胞乳腺癌（MBC）是乳腺肿瘤中的一个罕见亚组，因其侵袭性强而导致不良后果。MBC通常表现为激素受体（HR）三阴性。确定乳腺癌的激素受体状态是不可或缺的一部分，因为这是一个重要的预后因素，有助于疾病的治疗过程。本研究旨在确定 MBC 的 HR 状态、其重要性及其与各种临床病理参数的关系。研究方法这是一项在利亚卡特国立医院组织病理学部进行的回顾性研究。共有 140 例经活检证实的 MBC 病例参与研究。临床和病理数据均来自医院档案。免疫组化研究用于确定雌激素受体（ER）和孕激素受体（PR）的状态。结果我们发现，MBC患者的平均年龄为（52.18 ± 12.19）岁。HR阳性率为32.9%。HR状态与肿瘤侧位、肿瘤大小、肿瘤分级、肿瘤分期和复发之间存在明显关联。与ER/PR阳性的MBC（4.20 ± 1.88厘米）相比，ER/PR阴性的MBC很可能与肿瘤分级更高、肿瘤分期更高和肿瘤体积更大（6.62 ± 3.43厘米）有关。此外，ER/PR 阳性 MBC 的复发率高于ER/PR 阴性 MBC（分别为 43.5% 对 25.5%）。HR状态与患者年龄、组织学亚型或存活率之间没有统计学意义上的关系。结论：MBC是一种罕见的乳腺肿瘤。MBC是一种罕见的乳腺肿瘤。在大多数病例中，MBC 为三阴性，但有相当比例的病例为 HR（ER/PR）阳性。此外，我们还发现 HR 状态与各种临床病理特征之间存在关联，这表明 HR 状态是预测 MBC 预后的一个重要指标。
{"title":"Significance of Estrogen/Progesterone Receptor Expression in Metaplastic Breast Carcinoma","authors":"Atif Ali Hashmi, Bakhtawar Allauddin Mallick, Khushbakht Rashid, Umair Arshad Malik, Shamail Zia, Fazail Zia, Muhammad Irfan","doi":"10.1155/2024/2540356","DOIUrl":"https://doi.org/10.1155/2024/2540356","url":null,"abstract":"<i>Introduction</i>. Metaplastic breast carcinoma (MBC) is a rare subgroup of breast neoplasms associated with adverse outcomes because of its aggressive nature. Typically, MBCs show triple-negative hormone receptor (HR) status. Determining the HR status of breast cancer is an integral part because it is an important prognostic factor and helps in the treatment course of the disease. This study aimed to determine the HR status of MBC, its significance, and its association with various clinicopathological parameters. <i>Methods</i>. This was a retrospective study conducted at the Department of Histopathology, Liaquat National Hospital. A total of 140 biopsy-proven cases of MBC were enrolled in the study. Clinical and pathological data were retrieved from the institutes’ archives. Immunohistochemical studies were conducted to determine the estrogen receptor (ER) and progesterone receptor (PR) status. <i>Results</i>. The mean age of MBC in our population was found to be 52.18 ± 12.19 years. The HR positivity rate in our population was found to be 32.9%. A significant association was found between HR status and tumor laterality, tumor size, tumor grade, tumor stage, and recurrence. ER/PR-negative MBCs were most probably associated with higher grade and higher tumor stage and were larger in size (6.62 ± 3.43 cm) than ER/PR-positive MBCs (4.20 ± 1.88 cm). Moreover, ER/PR-positive MBCs showed a higher recurrence rate than ER/PR-negative MBCs (43.5% vs. 25.5%, respectively). No statistically significant relationship was found between HR status and patient age, histological subtype, or survival rate. <i>Conclusion</i>. MBC is a rare breast neoplasm. MBC was found to be triple negative in most cases, but a significant percentage were HR (ER/PR) positive. Moreover, we found an association between HR status and various clinicopathological features, indicating that HR status is a significant predictor of MBC prognosis.","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140562691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction. Lung cancer ranks first among malignant tumors worldwide and is a leading cause of cancer-related mortality in both men and women. Combining tumor marker testing is a strategy to screen individuals at high risk of pulmonary cancer and minimize pulmonary cancer mortality. Therefore, tumor marker screening is crucial. In this study, we analyzed combinations of tumor markers for lung cancer screening using receiver operating characteristic (ROC) curve analysis. Methods. A retrospective descriptive study was conducted on patients diagnosed with lung cancer, as well as healthy and benign lung diseases, using data from the China Huludao Central Hospital database between January 2016 and July 2022. The t-test and ROC curve were utilized to assess the effectiveness of individual tumor marker and the combination of multiple tumor markers. Tumor markers are molecular products metabolized and secreted by tumor tissues, characterized by cells or body fluids. They serve as indicators of tumor stage and grading, monitor treatment response, and predict recurrence. Results. In this study, 267 healthy participants, 385 patients with benign lesions, and 296 patients with lung cancer underwent tumor marker screening. The sensitivity of five tumor markers—CEA, CYFRA21-1, NSE, pro-GRP, and CA125—was found to be <55%. This study revealed that a single tumor marker had limited value in lung cancer screening. However, combining two or more markers yielded varying area under the curves (AUC), with no significant impact on screening accuracy. The combination of CEA + CA125 demonstrated the highest accuracy for lung cancer screening in healthy participants. At a cutoff of 0.447 for CEA + CA125, the combination showed a sensitivity of 0.676 and specificity of 0.846 for lung cancer screening. Conversely, for patients with benign lung lesions, the optimal combination was CEA + NSE, with a cutoff of 0.393, yielding a sensitivity of 0.645 and specificity of 0.766 for lung cancer screening. Conclusion. The five tumor markers—CEA, CA125, CY211, NSE, GRP—show promising results in screening healthy individuals and patients with lung cancer. However, only CEA, NSE, and GRP effectively differentiate patients with benign lung lesions from those with lung cancer. A single tumor marker has limited utility in detecting and screening for lung cancer and should be combined with other tumor markers. CEA + CA125 emerges as a superior tumor marker for distinguishing healthy individuals from those with lung cancer, whereas the CEA + NSE combination is more effective in identifying tumor markers in patients with benign lung lesions and lung cancer.
{"title":"Determination of Tumor Marker Screening for Lung Cancer Using ROC Curves","authors":"Xiaofeng Dou, Jiachen Lu, Yingying Yu, Yaohui Yi, Ling Zhou","doi":"10.1155/2024/4782618","DOIUrl":"https://doi.org/10.1155/2024/4782618","url":null,"abstract":"<i>Introduction</i>. Lung cancer ranks first among malignant tumors worldwide and is a leading cause of cancer-related mortality in both men and women. Combining tumor marker testing is a strategy to screen individuals at high risk of pulmonary cancer and minimize pulmonary cancer mortality. Therefore, tumor marker screening is crucial. In this study, we analyzed combinations of tumor markers for lung cancer screening using receiver operating characteristic (ROC) curve analysis. <i>Methods</i>. A retrospective descriptive study was conducted on patients diagnosed with lung cancer, as well as healthy and benign lung diseases, using data from the China Huludao Central Hospital database between January 2016 and July 2022. The <i>t</i>-test and ROC curve were utilized to assess the effectiveness of individual tumor marker and the combination of multiple tumor markers. Tumor markers are molecular products metabolized and secreted by tumor tissues, characterized by cells or body fluids. They serve as indicators of tumor stage and grading, monitor treatment response, and predict recurrence. <i>Results</i>. In this study, 267 healthy participants, 385 patients with benign lesions, and 296 patients with lung cancer underwent tumor marker screening. The sensitivity of five tumor markers—CEA, CYFRA21-1, NSE, pro-GRP, and CA125—was found to be <55%. This study revealed that a single tumor marker had limited value in lung cancer screening. However, combining two or more markers yielded varying area under the curves (AUC), with no significant impact on screening accuracy. The combination of CEA + CA125 demonstrated the highest accuracy for lung cancer screening in healthy participants. At a cutoff of 0.447 for CEA + CA125, the combination showed a sensitivity of 0.676 and specificity of 0.846 for lung cancer screening. Conversely, for patients with benign lung lesions, the optimal combination was CEA + NSE, with a cutoff of 0.393, yielding a sensitivity of 0.645 and specificity of 0.766 for lung cancer screening. <i>Conclusion</i>. The five tumor markers—CEA, CA125, CY211, NSE, GRP—show promising results in screening healthy individuals and patients with lung cancer. However, only CEA, NSE, and GRP effectively differentiate patients with benign lung lesions from those with lung cancer. A single tumor marker has limited utility in detecting and screening for lung cancer and should be combined with other tumor markers. CEA + CA125 emerges as a superior tumor marker for distinguishing healthy individuals from those with lung cancer, whereas the CEA + NSE combination is more effective in identifying tumor markers in patients with benign lung lesions and lung cancer.","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140198775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：